Search results for "Pharmaceutics"

showing 10 items of 552 documents

Local adaptation in populations of Mycobacterium tuberculosis endemic to the Indian Ocean Rim

2021

24 páginas, 3 figuras, 1 tabla. The sequence data generated by this study has been deposited on SRA (https://www.ncbi.nlm.nih.gov/sra) under the accession number PRJNA670836. Extended data is available here: https://github.com/fmenardo/MTBC_L1_L3. DOI: https://doi.org/10.5281/zenodo.4609804 (Menardo, 2021).

0301 basic medicineMycobacterium tuberculosis / patogenicidadeTuberculosisGenotypevirusesLineage (evolution)030106 microbiologyLocus (genetics)adaptationBiologyGenomeGeneral Biochemistry Genetics and Molecular BiologyMycobacterium tuberculosis03 medical and health sciencesAdapta??oGenoma BacterianomedicineHumansOceano ?ndico / epidemiologiaGeneral Pharmacology Toxicology and PharmaceuticsAdaptationIndian OceanLocal adaptationGenetic diversityGeneral Immunology and Microbiologyvirus diseasesTuberculose / patologiaGeneral MedicineArticlesMycobacterium tuberculosisbiochemical phenomena metabolism and nutritionbiology.organism_classificationmedicine.diseasedigestive system diseases3. Good health030104 developmental biologyMycobacterium tuberculosis complexEvolutionary biologycoevolutionLinhagemCoevolutionResearch ArticleF1000Research
researchProduct

The Anemonia viridis Venom: Coupling Biochemical Purification and RNA-Seq for Translational Research

2018

Blue biotechnologies implement marine bio-resources for addressing practical concerns. The isolation of biologically active molecules from marine animals is one of the main ways this field develops. Strikingly, cnidaria are considered as sustainable resources for this purpose, as they possess unique cells for attack and protection, producing an articulated cocktail of bioactive substances. The Mediterranean sea anemone Anemonia viridis has been studied extensively for years. In this short review, we summarize advances in bioprospecting of the A. viridis toxin arsenal. A. viridis RNA datasets and toxin data mining approaches are briefly described. Analysis reveals the major pool of neurotoxi…

0301 basic medicineNeurotoxinsPharmaceutical ScienceRNA-SeqVenomReviewComputational biologyCnidarian VenomAnemoniaTranslational Research Biomedicaltranscriptomics03 medical and health sciencescomputational biologyCnidarian VenomsDrug DiscoveryAnimalsData MiningMarine ToxinTranslational Medical Researchlcsh:QH301-705.5Pharmacology Toxicology and Pharmaceutics (miscellaneous)Sea AnemoneBioprospectingbiologyAnimalSequence Analysis RNASustainable resourcesDrug Discovery3003 Pharmaceutical ScienceRNAAnemonebio-prospectingbiology.organism_classificationSea Anemones030104 developmental biologyTranscriptomiclcsh:Biology (General)RNAMarine ToxinsNeurotoxinMarine toxinMarine Drugs
researchProduct

Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia.

2017

Several novel single nucleotide polymorphisms (SNPs) involved in cytarabine cytotoxicity and related to clinical outcomes have been reported recently in a series of 232 pediatric patients with acute myeloid leukemia (AML). We report the first adult AML cohort in which the influence of these SNPs in cytarabine efficacy and toxicity was analyzed. Six of polymorphisms with clinical significance in the previous study [rs12036333, rs10758713, rs9883101, rs6550826, IRX2: rs2897047, mutated in colorectal cancers (MCC): rs7729269] were analyzed in a cohort of 225 adult patients at initial diagnosis of AML treated with an induction scheme of idarubicin plus cytarabine. The variant alleles of rs12036…

0301 basic medicineOncologyAdultmedicine.medical_specialtyAdolescentPopulationSingle-nucleotide polymorphismKaplan-Meier EstimatePolymorphism Single NucleotideDisease-Free Survival03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineGeneticsmedicineIdarubicinHumansGeneral Pharmacology Toxicology and PharmaceuticseducationProspective cohort studyMolecular BiologyGenetics (clinical)Agededucation.field_of_studybusiness.industryCytarabineInduction chemotherapyMyeloid leukemiaInduction ChemotherapyMiddle AgedMinor allele frequencyLeukemia Myeloid Acute030104 developmental biology030220 oncology & carcinogenesisCytarabineMolecular Medicinebusinessmedicine.drugPharmacogenetics and genomics
researchProduct

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study

2019

BackgroundEribulin mesylate (E) is indicated for metastatic breast cancer patients previously treated with anthracycline and taxane. We argued that E could also benefit patients eligible for neoadjuvant chemotherapy.MethodsPatients with primary triple negative breast cancer ≥2 cm received doxorubicin 60 mg/m2 and paclitaxel 200 mg/m2 x 4 cycles (AT) followed by E 1.4 mg/m2 x 4 cycles. Primary endpoint was pathological complete response (pCR) rate; secondary and explorative endpoints included clinical/metabolic response rates and safety, and biomarker analysis, respectively. Using a two-stage Simon design, 43 patients were to be included provided that 4 of 13 patients had achieved pCR in the…

0301 basic medicineOncologyCancer TreatmentTriple Negative Breast NeoplasmsImmunostainingToxicologyPathology and Laboratory MedicineBiochemistryMetastasis0302 clinical medicineBreast TumorsClinical endpointMedicine and Health Sciencesmetastatic breast cancer Eribulin mesylate epithelial–mesenchymal transition.AnthracyclinesTriple-negative breast cancerStainingMultidisciplinaryPharmaceuticsQRKetonesMetastatic breast cancerNeoadjuvant TherapyTreatment OutcomeSurgical OncologyOncology030220 oncology & carcinogenesisMedicineFemaleTaxoidsResearch ArticleAdultBridged-Ring CompoundsClinical Oncologymedicine.medical_specialtyAnthracyclineScienceSurgical and Invasive Medical ProceduresNeutropeniaResearch and Analysis Methods03 medical and health sciencesCancer ChemotherapyBreast cancerbreast cancerDrug TherapyInternal medicinemedicineHumansChemotherapyFuransTaxaneToxicitybusiness.industryCancers and NeoplasmsBiology and Life Sciencesmedicine.disease030104 developmental biologySpecimen Preparation and TreatmentMED/06 - ONCOLOGIA MEDICAClinical MedicinebusinessBiomarkers
researchProduct

Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study.

2019

BackgroundIn this study based on the BRENDA data, we investigated the impact of endocrine ± chemotherapy for luminal A, nodal positive breast cancer on recurrence free (RFS) and overall survival (OS). In addition, we analysed if tumor size of luminal A breast cancer influences survival in patients with the same number of positive lymph nodes.MethodsIn this retrospective multi-centre cohort study data of 1376 nodal-positive patients with primary diagnosis of luminal A breast cancer during 2001-2008 were analysed. The results were stratified by therapy and adjusted by age, tumor size and number of affected lymph nodes.ResultsIn our study population, patients had a good to excellent prognosis …

0301 basic medicineOncologyDose-dense chemotherapyAdjuvant Chemotherapymedicine.medical_treatmentCancer Treatment0302 clinical medicineBreast TumorsMedicine and Health SciencesEndocrine TumorsMultidisciplinaryPharmaceuticsQREndocrine TherapyMiddle AgedPrognosisSurvival RateOncologyDocetaxelChemotherapy AdjuvantLymphatic Metastasis030220 oncology & carcinogenesisMedicineFemaleLymphAnatomyResearch Articlemedicine.drugClinical Oncologymedicine.medical_specialtyScienceBreast NeoplasmsDisease-Free SurvivalLymphatic SystemCancer Chemotherapy03 medical and health sciencesBreast cancerDrug TherapyDiagnostic MedicineInternal medicineBreast CancermedicineHumansChemotherapyEndocrine systemSurvival rateAgedRetrospective StudiesChemotherapybusiness.industryBiology and Life SciencesCancers and NeoplasmsRetrospective cohort studymedicine.disease030104 developmental biologyLymph NodesClinical MedicinebusinessPLoS ONE
researchProduct

New insights in primary ciliary dyskinesia

2017

Introduction: Primary ciliary dyskinesia (PCD) is a rare genetic disease with an estimated prevalence of 1:20.000 births. It is characterized by abnormal motility of cilia, leading to impaired mucociliary clearance, and subsequent infection and chronic inflammation of the airways. PCD also affects spermatozoa and cilia in the Fallopian tubes, contributing to fertility issues; dyskinesia of embryonic nodal cilia causes a random distribution of the organs. Areas covered: An overview of the history, genetics, clinical manifestations in children and adults, diagnostic tests, treatments, and prognosis are reviewed. We also discuss current research and future prospects of PCD. Expert opinion: As …

0301 basic medicinePathologymedicine.medical_specialtyDiagnostic methodsbusiness.industryHealth PolicyCiliumMotilityClinical featuresDiseaseDiagnostic methodsmedicine.disease03 medical and health sciencesPrimary ciliary dyskinesia030104 developmental biology0302 clinical medicine030228 respiratory systemGeneticsotorhinolaryngologic diseasesmedicinePharmacology (medical)TherapybusinessPharmacology Toxicology and Pharmaceutics (miscellaneous)Primary ciliary dyskinesia
researchProduct

Cystic fibrosis treatment: targeting the basic defect

2017

ABSTRACTIntroduction: Cystic Fibrosis (CF) is a disease caused by different class mutations in the CF transmembrane conductance regulator (CFTR) gene. It can therefore benefit from a personalized medicine approach based on the individual genotype of each patient.Areas covered: This review provides a detailed overview of the current major development of new CF treatments that target the basic CF defect. The review summarizes gene therapy, mRNA repair strategies, read-through agents, and CFTR-modulators (potentiators, correctors, stabilizers, amplifiers and different combination therapies).Expert opinion: We are currently perhaps at the most exciting stage in the history of CF, with the poten…

0301 basic medicinePathologymedicine.medical_specialtyMutationCombination therapybusiness.industryHealth PolicyGenetic enhancementDiseasePotentiatorBioinformaticsmedicine.diseasemedicine.disease_causeCystic fibrosisIvacaftor03 medical and health sciences030104 developmental biology0302 clinical medicine030228 respiratory systemMedicinePharmacology (medical)Personalized medicinebusinessPharmacology Toxicology and Pharmaceutics (miscellaneous)medicine.drugExpert Opinion on Orphan Drugs
researchProduct

Deviance sensitivity in the auditory cortex of freely moving rats.

2018

Deviance sensitivity is the specific response to a surprising stimulus, one that violates expectations set by the past stimulation stream. In audition, deviance sensitivity is often conflated with stimulus-specific adaptation (SSA), the decrease in responses to a common stimulus that only partially generalizes to other, rare stimuli. SSA is usually measured using oddball sequences, where a common (standard) tone and a rare (deviant) tone are randomly intermixed. However, the larger responses to a tone when deviant does not necessarily represent deviance sensitivity. Deviance sensitivity is commonly tested using a control sequence in which many different tones serve as the standard, eliminat…

0301 basic medicinePhysiologySensory Physiologylcsh:MedicineStimulationElectrode RecordingLocal field potentialAudiologyTetrodes0302 clinical medicineAnesthesiologyMedicine and Health SciencesAnesthesiaAudio Equipmentlcsh:ScienceMembrane ElectrophysiologyMultidisciplinaryPharmaceuticsBrainAdaptation PhysiologicalSensory SystemsLaboratory EquipmentSignal FilteringBioassays and Physiological AnalysisAuditory SystemVacuum ApparatusAuditory PerceptionEvoked Potentials AuditoryEngineering and TechnologyWakefulnessAnatomyPsychologyMicrophonesResearch ArticleAuditory perceptionmedicine.medical_specialtyComputer and Information SciencesHistologyEquipmentStimulus (physiology)Auditory cortexResearch and Analysis Methods03 medical and health sciencesDrug TherapymedicineAnimalsWakefulnessAuditory CortexControl Sequenceslcsh:RElectrophysiological TechniquesBiology and Life SciencesComputing MethodsRats030104 developmental biologyAcoustic StimulationSignal Processinglcsh:Q030217 neurology & neurosurgeryNeurosciencePloS one
researchProduct

Antimicrobial and Antibiofilm Activity of a Recombinant Fragment of β-Thymosin of Sea Urchin Paracentrotus lividus

2018

With the aim to obtain new antimicrobials against important pathogens such as Staphylococcus aureus and Pseudomonas aeruginosa, we focused on antimicrobial peptides (AMPs) from Echinoderms. An example of such peptides is Paracentrin 1 (SP1), a chemically synthesised peptide fragment of a sea urchin thymosin. In the present paper, we report on the biological activity of a Paracentrin 1 derivative obtained by recombination. The recombinant paracentrin RP1, in comparison to the synthetic SP1, is 22 amino acids longer and it was considerably more active against the planktonic forms of S. aureus ATCC 25923 and P. aeruginosa ATCC 15442 at concentrations of 50 &micro

0301 basic medicineSettore BIO/05 - ZoologiaPharmaceutical Science<i>Staphylococcus aureus</i>Peptide<i>Paracentrotus lividus</i>Settore BIO/19 - Microbiologia Generalemedicine.disease_causebiofilmDrug DiscoveryPharmacology Toxicology and Pharmaceutics (miscellaneous)lcsh:QH301-705.5chemistry.chemical_classificationbiologyMicrobial Sensitivity TestChemistrymolecular dynamicBiological activityRecombinant ProteinAntimicrobialRecombinant ProteinsAnti-Bacterial AgentsBiochemistrySettore CHIM/03 - Chimica Generale E InorganicaStaphylococcus aureusPeptidePseudomonas aeruginosaStaphylococcus aureuParacentrotusAntibacterial activityAMP (antimicrobial peptides)Staphylococcus aureusSea UrchinAntimicrobial peptidesMicrobial Sensitivity TestsParacentrotus lividusArticle03 medical and health sciencesAnti-Bacterial AgentmedicineAnimalsAMP (antimicrobial peptides); Paracentrotus lividus; Pseudomonas aeruginosa; Staphylococcus aureus; biofilm; molecular dynamics; thymosinAnimalBiofilmthymosinbiology.organism_classificationmolecular dynamics<i>Pseudomonas aeruginosa</i>030104 developmental biologylcsh:Biology (General)Paracentrotus lividusBiofilmsSea UrchinsParacentrotuPeptidesParacentrotus lividuMarine Drugs
researchProduct

Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice.

2017

Breaking tolerance is crucial for effective tumor immunotherapy. We showed that vaccines containing tumor-associated human MUC1 glycopeptides induce strong humoral antitumor responses in mice. The question remained whether such vaccines work in humans, in systems where huMUC1 is a self-antigen. To clarify the question, mice transgenic in expressing huMUC1, mimicking the self-tolerant environment, and wild-type mice were vaccinated with a synthetic vaccine. This vaccine comprised STn and Tn antigens bound to a MUC1 tandem repeat peptide coupled to tetanus toxoid. The vaccine induced strong immune responses in wild-type and huMUC1-transgenic mice without auto-aggressive side effects. All anti…

0301 basic medicineSynthetic vaccinemedicine.medical_treatmentBreast NeoplasmsMice TransgenicBiology01 natural sciencesBiochemistryCancer Vaccines03 medical and health sciencesImmune systemAntigenCancer immunotherapyDrug DiscoverymedicineTetanus ToxoidAnimalsHumansAntigens Tumor-Associated CarbohydrateGeneral Pharmacology Toxicology and PharmaceuticsPharmacologyVaccines Synthetic010405 organic chemistryTetanusOrganic ChemistryMucin-1ToxoidImmunotherapymedicine.diseaseVirologyPeptide Fragments0104 chemical sciencesMice Inbred C57BL030104 developmental biologyImmunizationImmunologyMCF-7 CellsMolecular MedicineFemaleImmunizationChemMedChem
researchProduct